Meeting
2015 ASCO Annual Meeting
A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01.
Authors
Jeffrey J. Raizer
Lurie Comp Cancer Ctr of Northwestern Univ, Chicago, IL
Jeffrey J. Raizer , Sean Aaron Grimm , Marta Penas-Prado , Ivo Tremont-Lukats , W. K. Alfred Yung , Nicholas George Avgeropoulos , Tobias Walbert , Monica Elena Loghin , Mark R. Gilbert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01434602
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2061)
DOI
10.1200/jco.2015.33.15_suppl.2061
Abstract #
2061
Poster Bd #
50
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.
First Author: Shannon Neville Westin
Poster
2011 ASCO Annual Meeting
A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727).
First Author: E. Jonasch
Poster
2021 ASCO Annual Meeting
Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.
First Author: David Starks
Poster
2016 ASCO Annual Meeting
A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors.
First Author: Lakshmi Nayak